Search Results

You are looking at 51 - 60 of 188 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Vivian E. Strong, Thomas A. D’Amico, Lawrence Kleinberg, and Jaffer Ajani

regarding the assignment of therapy: which patients should be considered to have a surgically curable tumor based on nodal status? Although various surgical approaches may be used, adequate lymph node dissection should accompany the resection, either a 2

Full access

Melinda L. Telli, William J. Gradishar, and John H. Ward

. Patients with positive needle biopsy results for whom upfront surgery is planned have several options. The patient can proceed with an axillary lymph node dissection (ALND) or, if she meets all the ACOSOG Z0011 trial criteria 3 and also has low tumor

Full access

Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, Michael Korn, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright, and Gary Yang

with positive margins, is acceptable for symptomatic palliation of bleeding in unresectable tumors. Palliative gastric resection should not be performed unless the patient is symptomatic and lymph node dissection is not required (page 386). Gastric

Full access

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani

Retrospective studies indicate that more extensive lymph node dissection improves outcomes over less extensive nodal dissection. 20 , 21 However, randomized trials comparing patients undergoing D1 lymphadenectomy (dissection of perigastric lymph nodes) with

Full access

Andrew K. Lee and Christopher L. Amling

surveillance. Preoperative knowledge of the probability of finding high-grade disease in the prostate specimen may also alter surgical technique or the decision to perform lymph node dissection. Chun et al. 18 , 19 developed 2 nomograms, one predicting Gleason

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder

retroperitoneal lymph node dissection (RPLND), it is recommended between 3 to 6 months postsurgery and then as clinically indicated. 39 The follow-up of patients with stage IIB seminoma after chemotherapy is similar to follow-up after chemotherapy for patients

Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea

alone with radical hysterectomy and lymph node dissection. 40 This study used adjuvant RT after surgery for women with surgical stage pT2b (which corresponds to FIGO stage IIB) or more extensive disease, less than 3 mm of uninvolved cervical stroma, and

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

lymph node dissection (RPLND) may be considered (category 2A). The other option, if resection is not feasible, is second-line chemotherapy (category 2A). Cisplatin-based combination chemotherapy is used for second-line treatment. 77 – 79 The regimens

Full access

Stephen B. Edge

Krag DN Anderson SJ Julian TB . Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

Full access

Christopher K. Bichakjian, Thomas Olencki, Murad Alam, James S. Andersen, Daniel Berg, Glen M. Bowen, Richard T. Cheney, Gregory A. Daniels, L. Frank Glass, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Daniel D. Lydiatt, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Clifford S. Perlis, Ashok R. Shaha, Wade L. Thorstad, Malika Tuli, Marshall M. Urist, Timothy S. Wang, Andrew E. Werchniak, Sandra L. Wong, John A. Zic, Karin G. Hoffmann, Nicole R. McMillian, and Maria Ho

participating NCCN Member Institutions use the SLNB technique routinely for MCC, as they do for melanoma. The panel believes that identifying patients with positive microscopic nodal disease and then performing full lymph node dissections or RT maximizes the